Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 34 clinical trials
A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

The study is being conducted to evaluate the tolerability, safety and efficacy of maintenance Fluzoparib monotherapy in patients with gBRCA/PALB2 mutated metastatic pancreatic cancer whose

cancer
blood test
palb2
adenocarcinoma
pancreatic adenocarcinoma
  • 0 views
  • 01 Feb, 2021
  • 23 locations
Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency

Talazoparib has shown clinical efficacy in breast cancer patients with germline BRCA1 or BRCA2 mutations. Beyond BRCA1 and BRCA2 mutations, it is plausible that talazoparib may have activity in patients with homologous recombination defects (HRD).

  • 0 views
  • 28 May, 2021
  • 1 location
Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer

PERSEUS1 is an open-label, single arm, phase II trial evaluating the efficacy of Pembrolizumab in metastatic castration resistant prostate cancer (mCRPC) patients (Part A) with a biomarker enrichment stage (Part B) if efficacy is shown in part A.

soft tissue disease
adenocarcinoma
testosterone
tumor progression
major surgery
  • 0 views
  • 24 Jan, 2021
  • 1 location
COsegregation of VARiants in Panel of Genes

The aim of the COVAR project is to classify reliably a maximum of VUS of the French database in order to use them for the genetic counseling. The results obtained through this study will have a major impact on clinical management of the patients and their families conducting in some …

BRCA2
BRCA1/2
breast cancer
palb2
KIT
  • 17 views
  • 09 Aug, 2021
  • 88 locations
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors

PALB2 (tPALB2) mutation.

solid tumor
formalin-fixed paraffin-embedded
corticosteroid
palb2
  • 0 views
  • 24 May, 2022
  • 50 locations
Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer

This phase II trial studies how well niraparib and dostarlimab work in treating patients with germline or somatic BRCA1/2 and PALB2 mutated pancreatic cancer that has spread to other places in

  • 0 views
  • 10 Jul, 2021
  • 5 locations
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

This is an open-label, multi-center, phase 1b study designed to determine a tolerable dose of CX-5461 administered by IV infusion on Day 1 and Day 8 of a 28-day cycle in patients with selected solid tumours and associated mutations for future Phase II trials. The safety and tolerability of CX-5461, …

  • 1 views
  • 24 May, 2022
  • 4 locations
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer (COBRA)

BRCA1, BRCA2 or PALB2 inactivating DNA mutations. Participants are randomized (1:1) and receive either carboplatin (AUC 5, IV) every 21 days, first or olaparib taken orally (300 mg), twice daily

  • 14 views
  • 10 Apr, 2022
  • 11 locations
A Randomized Study of Olaparib or Placebo in Patients With Surgically Removed Pancreatic Cancer Who Have a BRCA1, BRCA2 or PALB2 Mutation, The APOLLO Trial

removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP

BRCA2
palb2
adenocarcinoma
carcinoma
BRCA1
  • 0 views
  • 14 May, 2022
  • 124 locations
Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer. (RADIOLA)

The primary objetive is to assess the capacity of the RAD51-foci score to predict the efficacy of olaparib in BRCA1/2, PALB2 or RAD51C/D mut advanced breast cancer (cohort 1). The

  • 0 views
  • 04 May, 2022
  • 1 location